Modifier genes and their effect on Duchenne muscular dystrophy

Area of Science:

• Genetics
• Molecular Biology
• Biomarkers

Background:

• Genetic pathways influencing Duchenne muscular dystrophy (DMD) clinical severity are increasingly recognized.
• Understanding these modifiers aids in predicting disease progression and identifying therapeutic targets.

Purpose of the Study:

• To review recently identified genetic pathways that modify Duchenne muscular dystrophy (DMD) severity.
• To highlight the utility of these modifiers in prognosis prediction and therapeutic development.

Main Methods:

• Gene expression profiling and genome-wide screens were employed to identify genetic modifiers.
• Validation of identified modifiers was performed in cohorts of DMD patients.

Main Results:

• Osteopontin (SPP1 gene) and latent TGFβ binding protein 4 were identified through gene expression and genome-wide screens, respectively, both regulating TGFβ.
• Anxa6, a calcium-binding protein, was identified in mouse models and regulates sarcolemmal repair pathways.

Conclusions:

• Genetic modifiers serve as valuable biomarkers for DMD outcomes, influencing strength and ambulation.
• These modifiers can be utilized as endpoints in clinical trials for Duchenne muscular dystrophy.
• Consideration of genetic markers is crucial for stratifying results in muscular dystrophy research and treatment.